Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (via FOI)에 따르면, 해당 현장 안전성 서한 는
Slovenia
에서 Roche 에 의해 제조된 제품과 관련되어 있습니다.
이것은 무엇인가요?
현장 안전성 서한은 의료기기 제조사 또는 제조사 대리인이 시중에 유통되고 있는 자사 의료기기 제품에 대하여 취할 수 있는 조치를 알리는 소통방식입니다. 주요 대상층은 보건의료업계 종사자와 의료기기 사용자들입니다. 여기에는 회수(recall) 조치와 경고도 포함될 수 있습니다.
Data from Slovenia is current through February 2019. All of the data comes from the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (via FOI), except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Slovenia.
데이터 추가 비고
원인
The ifus (instructions for use) for vancomycin on cobas c 311/501/502 and modular analytics p-module
state an incorrect method comparison against cobas integra® 800.
since the cobas integra reagent is not yet adapted, results generated with cobas integra are still up to 20 %
higher than with cobas c or modular analytics p-module. the method comparison shown may lead to the
assumption that both methods are comparable and may affect the interpretation of vancomycin test results.
the issue can potentially lead to misinterpretation of results. in case that the first result has been generated with
integra and the following result using cobas/hitachi assay, the difference between assays might be interpreted
as decrease in vancomycin concentration which can further trigger the increase in the dosage. in this case, a
.